Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
[This corrects the article DOI: 10.3389/fnins.2019.00394.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001677 | PMC |
| http://dx.doi.org/10.3389/fnins.2019.01344 | DOI Listing |
Publication Analysis
Top Keywords
corrigendum 2-pyrrolidinone
4
2-pyrrolidinone succinimide
4
succinimide clinical
4
clinical screening
4
screening biomarkers
4
biomarkers gaba-transaminase
4
gaba-transaminase deficiency
4
deficiency anti-seizure
4
anti-seizure medications
4
medications impact
4
Similar Publications
Corrigendum: 2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis.
Front Neurosci
January 2020
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States.
Article Synopsis
- The text refers to a correction of an article published with the DOI 10.3389/fnins.2019.00394.
- This correction indicates that there were errors or updates needed for the original publication.
- It emphasizes the importance of accuracy and transparency in scientific literature.